- Home
- TTGT vs ITOS Comparison
TTGT vs ITOS Comparison
Compare TTGT & ITOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTGT
- ITOS
- Stock Information
- Founded
- TTGT 1999
- ITOS 2011
- Country
- TTGT United States
- ITOS United States
- Employees
- TTGT N/A
- ITOS N/A
- Industry
- TTGT Telecommunications Equipment
- ITOS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TTGT Telecommunications
- ITOS Health Care
- Exchange
- TTGT Nasdaq
- ITOS Nasdaq
- Market Cap
- TTGT 468.3M
- ITOS 450.9M
- IPO Year
- TTGT 2007
- ITOS 2020
- Fundamental
- Price
- TTGT $5.85
- ITOS N/A
- Analyst Decision
- TTGT Strong Buy
- ITOS Hold
- Analyst Count
- TTGT 5
- ITOS 6
- Target Price
- TTGT $16.40
- ITOS $10.40
- AVG Volume (30 Days)
- TTGT 621.7K
- ITOS 1.6M
- Earning Date
- TTGT 11-11-2025
- ITOS 08-06-2025
- Dividend Yield
- TTGT N/A
- ITOS N/A
- EPS Growth
- TTGT N/A
- ITOS N/A
- EPS
- TTGT N/A
- ITOS N/A
- Revenue
- TTGT $387,100,000.00
- ITOS N/A
- Revenue This Year
- TTGT N/A
- ITOS N/A
- Revenue Next Year
- TTGT $99.41
- ITOS N/A
- P/E Ratio
- TTGT N/A
- ITOS N/A
- Revenue Growth
- TTGT 50.73
- ITOS 177.89
- 52 Week Low
- TTGT $5.39
- ITOS $4.80
- 52 Week High
- TTGT $33.08
- ITOS $17.63
- Technical
- Relative Strength Index (RSI)
- TTGT 44.13
- ITOS 1.63
- Support Level
- TTGT $5.54
- ITOS $10.10
- Resistance Level
- TTGT $5.95
- ITOS $10.17
- Average True Range (ATR)
- TTGT 0.34
- ITOS 0.02
- MACD
- TTGT 0.05
- ITOS -0.80
- Stochastic Oscillator
- TTGT 51.11
- ITOS 0.00
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About ITOS iTeos Therapeutics Inc.
ITeos Therapeutics Inc is a biopharmaceutical company. It designs novel product candidates with optimized pharmacologic properties to improve clinical outcomes by restoring the immune response against cancer. The company's product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist, and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody among other drug candidates.